Data Mining, Experiments ID QT Prolonging Drug Interactions

Share this content:
Data Mining, Experiments ID QT Prolonging Drug Interactions
Data Mining, Experiments ID QT Prolonging Drug Interactions

MONDAY, Oct. 17, 2016 (HealthDay News) -- Data mining coupled with laboratory experiments can identify QT interval-prolonging drug-drug interactions (QT-DDIs), according to a study published in the Oct. 18 issue of the Journal of the American College of Cardiology.

Tal Lorberbaum, from Columbia University in New York City, and colleagues mined 1.8 million adverse event reports for signals indicating a QT-DDI. These interactions were either refuted or corroborated using 1.6 million electrocardiogram results from 380,000 patients in an institutional electronic health record (EHR).

The researchers identified evidence from direct and indirect signals in the adverse event reports that the combination of ceftriaxone and lansoprazole would prolong the QT interval. Patients taking both ceftriaxone and lansoprazole had significantly longer QTc intervals as seen in the EHR, and were 1.4 times more likely to have a QTc interval >500 ms. These drugs blocked the human ether-à-go-go-related gene channel in the laboratory. Use of the combination of lansoprazole and cefuroxime as a negative control exhibited no significant effect in the EHR or electrophysiology experiments. This interaction was specific to lansoprazole combined with ceftriaxone in class effect analyses.

"Coupling data mining and laboratory experiments is an efficient method for identifying QT-DDIs," the authors write. "Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquired long QT syndrome."

One author disclosed financial ties to Advera Health; one author disclosed ties to Azcert.org.

Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »